Probiotic Treatment for Uveitis

Not Applicable

• Conditions: Health Condition 1: H15-H22- Disorders of sclera, cornea, iris and ciliary body

• Registration Number: CTRI/2019/07/020245
• Lead Sponsor: Hyderabad Eye Research Foundation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Other (Terminated)
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Ability to give informed consent for participation.

2.Males or females greater than or equal to 18 years of age.

3.Patients and controls should not have received antibiotics, pro- or prebiotic treatment for at least three months prior to sample collection.

4.Patients with Non-granulomatous anterior uveitis.

5.Presenting AC reaction greater than or equal to grade 2.

6.Onset less than or equal to 2 weeks.

7.HLA-B27 positive

8.All cohorts are matched for diet, age, gender, ethnicity etc.

9.Rule out infectious etiology

Exclusion Criteria

1.Posterior segment inflammation more than spillover vitritis.

2.Active infectious uveitis

3.Lens induced uveitis

4.Non-HLA-B27 associated uveitis

5.Any significant systemic or ocular disease that could compromise the uveitis in the study eye. These include, but are not limited to:

a.Diabetic retinopathy: proliferative diabetic retinopathy (PDR) or non-proliferative diabetic retinopathy (NPDR).

b.Wet age-related macular degeneration.

c.Myopic degeneration with active sub-foveal choroidal neovascularization.

d.Uncontrolled glaucoma, intraocular pressure of > 21 mm Hg while on medical therapy, or chronic hypotony ( <6 mm Hg).

6.Any implantable corticosteroid-eluting device (e.g. Ozurdex, I-vation, triamcinolone acetonide [TA] intravitreal implant) in the study eye within the past 90 days.

7.Any of the following treatments within 90 days prior to enrollments:

a.Intravitreal injections (including steroids and anti-vascular endothelial growth factors);

b.Posterior subtenon steroids.

8.Free from antibiotic and systemic immunosuppressant use (three months prior to presentation and during the course of study).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
a.To demonstrate that concurrent probiotic therapy during standard treatment for HLA-B27 associated AU facilitates faster remission of clinical inflammation. <br/ ><br>b.To demonstrate that probiotic therapy helps in prevention of relapse in patients with quiescent HLA-B27 associated AU.Timepoint: 1 Week, 4 Weeks, 8 weeks

Secondary Outcome Measures

Name	Time	Method
To monitor pro-inflammatory cytokines in serum of patients prior to and after probiotic therapyTimepoint: 1 Week, 4 Weeks, 8 weeks